Poly (ADP-ribose) polymerase (PARP) is a family of enzymes found naturally and abundantly throughout the human body. PARP-1 plays a central role in cell proliferation and signaling to other critical cell cycle proteins and oncogenes and in DNA repair.
PARP is a well-accepted and validated target for cancer therapies. BiPar’s novel, proprietary PARP inhibitors are the first of a new generation of drug candidates that show promising activity and a favorable toxicity profile. Preclinical studies suggest the drugs selectively induce tumor cell death and are active against a broad range of tumor types.
Learn more about the candidates in our PARP Inhibitor Program:
- BSI-201: Lead Product and Clinical Stage PARP Inhibitor (IV)
- BSI-401: Follow-on PARP Inhibitor (Oral)
Learn more about our BSI-301: Preclinical Stage Iodothyronine Anti-tubulin Program.
